GLP-1 Receptor Agonists Show Varied Weight Loss Responses in White vs. Black Adults
Background
GLP-1 Receptor Agonists (GLP-1RAs) are highly effective medications widely used for managing obesity and type 2 diabetes, promoting significant weight loss and improving metabolic health. However, real-world treatment outcomes can vary considerably among individuals, and health disparities based on race and ethnicity are a persistent concern in medicine. This study addresses a critical knowledge gap by investigating potential differences in the efficacy of GLP-1RAs for weight loss between White and Black adults with obesity using a large dataset of electronic health records.
Results
The analysis revealed statistically significant differences in weight loss responses between racial groups. On average, White adults with obesity achieved a mean total body weight loss of 8.7% over 12 months of GLP-1RA treatment. In contrast, Black adults experienced a mean total body weight loss of 6.1% during the same period, indicating a notable disparity. These differences remained significant (p<0.001) even after adjusting for baseline BMI, age, sex, comorbidities, and duration of therapy. > The study's most critical finding was that Black adults with obesity experienced a significantly lower average percentage of total body weight loss by approximately 2.6 percentage points compared to White adults when treated with GLP-1RAs. Furthermore, the models suggested that the rate of weight loss plateaued earlier in Black adults, with a 1.5-fold slower initial response in some subgroups.
Why It Matters
These findings underscore the critical importance of recognizing and addressing racial disparities in treatment efficacy for obesity management. Understanding these differences in GLP-1RA response is crucial for developing more equitable and personalized medicine approaches. This research could directly inform clinical guidelines, prompting healthcare providers to consider race-specific factors and potentially tailor treatment strategies or explore alternative interventions for Black patients with obesity. Future research should delve into the underlying biological (e.g., genetic, metabolic), socioeconomic, or environmental factors contributing to these observed disparities, potentially leading to targeted therapeutic developments or public health initiatives.